Quantification of pravastatin in human plasma and urine after solid phase extraction using high performance liquid chromatography with ultraviolet detection

被引:39
作者
Bauer, S [1 ]
Mwinyi, J [1 ]
Stoeckle, A [1 ]
Gerloff, T [1 ]
Roots, I [1 ]
机构
[1] Univ Med Berlin, Charite, Inst Clin Pharmacol, D-10098 Berlin, Germany
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2005年 / 818卷 / 02期
关键词
pravastatin; OATP-C; pharmacokinetic;
D O I
10.1016/j.jchromb.2005.01.006
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A high performance liquid chromatography (HPLC) method for the estimation of pravastatin in human plasma and urine samples has been developed. The preparation of the samples was performed by automated solid phase extraction using clonazepam as internal standard. The compounds were separated by isocratic reversed-phase HPLC (C-18) and detected at 239 nm. The method was linear up to concentrations of 200 ng/ml in plasma and 2000 ng/ml in urine. The intra-assay variability for pravastatin in plasma ranged from 0.9% to 3.5% and from 2.5% to 5.3% in urine. The inter-assay variability ranged from 9.1% to 10.2% in plasma and from 3.9% to 7.5% in urine. The validated limits of quantification were 1.9 ng/ml for plasma and 125 ng/ml for urine estimation. These method characteristics allowed the determination of the pharmacokinetic parameters of pravastatin after administration of therapeutic doses. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:257 / 262
页数:6
相关论文
共 17 条
[1]   HIGHLY SENSITIVE AND SPECIFIC DETERMINATION OF PRAVASTATIN SODIUM IN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH LASER-INDUCED FLUORESCENCE DETECTION AFTER IMMOBILIZED ANTIBODY EXTRACTION [J].
DUMOUSSEAUX, C ;
MURAMATSU, S ;
TAKASAKI, W ;
TAKAHAGI, H .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1994, 83 (11) :1630-1636
[2]   Pharmacokinetics and pharmacodynamics of pravastatin in children with-familial hypercholesterolemia [J].
Hedman, M ;
Neuvonen, PJ ;
Neuvonen, M ;
Antikainen, M .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (02) :178-185
[3]   A novel human hepatic organic anion transporting polypeptide (OATP2) - Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters [J].
Hsiang, BN ;
Zhu, YJ ;
Wang, ZQ ;
Wu, YL ;
Sasseville, V ;
Yang, WP ;
Kirchgessner, TG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (52) :37161-37168
[4]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY DETERMINATION OF PRAVASTATIN IN PLASMA [J].
IACONA, I ;
REGAZZI, MB ;
BUGGIA, I ;
VILLANI, P ;
FIORITO, V ;
MOLINARO, M ;
GUARNONE, E .
THERAPEUTIC DRUG MONITORING, 1994, 16 (02) :191-195
[5]  
Kawabata K, 1998, BIOMED CHROMATOGR, V12, P271, DOI 10.1002/(SICI)1099-0801(199809/10)12:5<271::AID-BMC746>3.3.CO
[6]  
2-6
[7]  
KOBAYASHI D, 2003, J PHARMACOL EXP THER, V30, P30
[8]   Possible active transport mechanism in pharmacokinetics of flunixin-meglumin in rabbits [J].
Miyazaki, Y ;
Horii, Y ;
Ikenaga, N ;
Shimoda, M ;
Kokue, E .
JOURNAL OF VETERINARY MEDICAL SCIENCE, 2001, 63 (08) :885-888
[9]   Quantitative determination of pravastatin and its biotransformation products in human serum by turbo ion spray LC/MS/MS [J].
Mulvana, D ;
Jemal, M ;
Pulver, SC .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2000, 23 (05) :851-866
[10]   Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics [J].
Mwinyi, J ;
Johne, A ;
Bauer, S ;
Roots, I ;
Gerloff, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (05) :415-421